Interview with Novocell CEO Alan Lewis
In this StemCellPatents.com interview, our special guest interviewer, Thomas Ichim, CEO of Medistem, speaks with Alan Lewis, CEO of Novocell, regarding the company's advances towards curing diabetes. This interview examines many aspects of Novocell which... [Read more]
FGF-1 Gene Therapy Double Blind Trial
Münster, Germany -
Understanding and manipulating the formation of new blood vessels, a process called angiogenesis, has been one of the highly sought-after goals of the biotechnology industry. One the one hand, inhibition of angiogenesis is desirable in cancer, since tumors need new blood vessels to stay alive. On the other hand, angiogenesis stimulation could... [Read more]
Parathyroid hormone mobilization and limb ischemia
Naples, Italy -
The administration of bone marrow stem cells into ischemic muscles for treatment of critical limb ischemia is currently being performed in clinical trials, with results demonstrating stimulation of angiogenesis and functional improvement. Given that a substantial amount of the angiogenic response seems to... [Read more]
Menstrual Blood Stem Cells Part 2
Tokyo, Japan -
It was previously reported by the company Medistem (mdsm.ob) that a population of multipotent stem cells exist in menstrual blood. These cells, which Medistem termed "endometrial regenerative cells" appear to possess some of the properties of mesenchymal stem cells, such as expression of CD90 and... [Read more]
Expanding Hematopoietic Stem Cells by Removing Inhibitors
The desire to expand hematopoietic stem cells is not only a basic research accomplishment but would allow for widespread use of autologous stem cells, as well as expand the utilization of cord blood stem cells which are usually of concern due to the relatively low stem cell content.
Various methods of expanding hematopoietic stem cells exist, for example, Tokyo, Japan - Embryonic stem cells have a very high potential to generate various tissues, a potential so high that it actually serves as a drawback in some senses. See, embryonic stem cells, when grown in floating cultures form embryoid bodies, and in these embryoid bodies the embryonic stem cell starts differentiating into a wide... [Read more]
"I need blood" says the embryoid body
Go to News Section
- Patent Spotlight - Multi-lineage directed induction of bone marrow stromal cell differentiation - 7,364,900
- Loop peptide and TGF.alpha. for stimulating stem cell proliferation and migration - 7,365,172
- Methods of cancer therapy targeted against a cancer stem line - 7,361,336
- Multipotent neural stem cell compositions - 7,361,505
StemCellPatents.com Journal
The recent funding of Fate Therapeutics as a company dedicated to identification of pharmacological stem cell activators is a great step for the industry. Essentially, the concept of the company is that one day one will be able to activate one's own stem cells through taking various chemical compounds. This concept is not new, companies such as Stem Cell Therapeutics are already in Phase II clinical trials with such approaches.
In the current mini-article, we will discuss the ability of a compound that has been clinically used for decades as potential modulator of endogenous stem cells.
Note:
> Publish your article!
Latest Job Postings
Patent Proscecution Technology Specialist or Scientific AdvisorBoston
Attorney- Patent Litigation Associate
Boston
